Japan records surprise trade deficit in July as exports weaken further
Barnes Kelly Ann, a director at Fractyl Health , Inc. (NASDAQ:GUTS), has recently acquired 31,000 shares of the company’s common stock. The purchase, made on March 14, 2025, was executed at an average price of $1.2971 per share, totaling approximately $40,210. This transaction increases Barnes’ direct ownership in the company to 31,000 shares. The purchase comes as the stock trades near its 52-week low of $1.16, having declined nearly 80% over the past year. According to InvestingPro data, analysts maintain price targets ranging from $6 to $10 per share.
Fractyl Health, headquartered in Burlington (NYSE:BURL), Massachusetts, is known for its work in the surgical and medical instruments sector. The company’s stock is traded under the ticker GUTS on the NASDAQ exchange. With a market capitalization of $62 million, the company currently shows a WEAK financial health score according to InvestingPro analysis, which offers 13 additional key insights about the company’s performance and outlook in its comprehensive Pro Research Report.
In other recent news, Fractyl Health announced its Q4 2024 earnings, revealing a larger-than-expected loss with an EPS of -$0.52, which fell short of analysts’ predictions of -$0.42. The company’s revenue was primarily generated from a commercial pilot in Germany, while research and development expenses rose significantly to $20.3 million, up from $10.1 million in Q4 2023. Selling, general, and administrative expenses also increased to $4.9 million compared to $2.8 million the previous year. Fractyl Health’s net loss for the quarter amounted to $25 million, up from $19.2 million in Q4 2023. The company holds $67.5 million in cash and cash equivalents as of December 31, 2024, which is expected to sustain operations through key milestones into 2026. In other developments, Fractyl Health has set June 11, 2025, as the date for its annual stockholder meeting, following the absence of a meeting in 2024. Additionally, the company is focusing on advancing its RAVITA and REJUVA platforms, with key clinical milestones anticipated in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.